
Opinion|Videos|May 6, 2024
A New Era in PAH Treatment?
Author(s)Marius Hoeper, MD
An expert on pulmonary arterial hypertension discusses the potential impact of emerging therapies, including sotatercept, ralinepag, and inhaled imatinib.
Advertisement
Episodes in this series

Video content above is prompted by the following question:
- What is your assessment of the potential clinical impact of new or emerging pulmonary arterial hypertension (PAH) therapies, such as sotatercept, ralinepag, and inhaled imatinib, in terms of reducing hospitalizations or need for supportive care and improving long-term patient outcomes and quality of life?
Advertisement
Related to this article

A scalable, symptom-focused patient education model paired with coordinated podiatric care offers managed care organizations a low-barrier strategy to reduce diabetic foot ulcers and costly amputations.

Pimicotinib, a once-daily oral CSF-1R inhibitor, is now FDA approved for adults with TGCT for whom surgery may worsen function or cause severe morbidity.

Pooled real-world data show an 88% response rate with brexu-cel in relapsed mantle cell lymphoma (MCL), but cost and QOL data are scarce.

Employer diabetes guide; Camden psychedelic therapy input; CRC after EMR; rural HFrEF care; JAMA obesity report.

This article analyzes gaps in US biosimilar development, quantifies market opportunities, and proposes policy and economic solutions to improve cost savings and patient access.

During OncoVenture, Careology leaders described how their platform supports patients receiving CAR T-cell therapy at home in Ohio, extends Mayo Clinic’s reach in rural Florida, and powers payer care navigation.

John Elliott, of Reimagine Care, outlined a model that pairs AI-supported triage with oncology-trained nurses, and the CEO of a large Texas practice described how the partnership has grown to include patients receiving CAR T-cell therapy.
Advertisement
Advertisement
Trending on AJMC
1
Health Equity & Access Weekly Roundup: November 20, 2026
2
Defining High-Efficacy MS Therapy: Access, Formularies, and Patient Choice
3
FDA Approves Pimicotinib for Symptomatic Tenosynovial Giant Cell Tumor
4
Caregiving Cuts Across Party Lines: Sen Andy Kim
5



